The landscape of Alzheimer's treatment is evolving rapidly. At the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference, researchers presented breakthrough data on treatments that go far beyond amyloid-clearing therapies like Leqembi and Kisunla.

In this podcast episode, I break down seven treatments that could be available—or very close to available—in 2026:

1. Remternetug - Anti-tau antibody that could be combined with existing treatments

2. ALZ-801 - Oral amyloid blocker (no infusions required)

3. Masitinib - Anti-inflammatory targeting neuroinflammation

4. Fosgonimeton - Synaptic restoration therapy

5. Gantenerumab - High-dose amyloid therapy showing renewed promise

6. Semaglutide (Ozempic) - Repurposed diabetes drug with neuroprotective effects

7. Combination therapy trials - Multiple mechanisms working together

We're also seeing a major shift toward earlier intervention—treating people before symptoms appear using biomarker testing, blood tests, and PET scans.

What this means for families:

• More treatment options beyond current FDA-approved therapies

• Oral medications in development (reducing infusion burden)

• Different mechanisms for patients who don't respond to amyloid-clearing therapies

• Earlier intervention strategies that could preserve more function

What you should do now:

• Maximize current treatment options (Leqembi, Kisunla)

• Consider clinical trial participation

• Explore biomarker testing if you're at risk

• Stay informed about the treatment pipeline

• Connect with research centers and advocacy organizations

Listen to the full episode for detailed analysis of each treatment, FDA approval timelines, patient eligibility criteria, and actionable steps you can take today.